Because MCL1 has been shown to be both an intrinsic and acquired resistance factor that limits the efficacy of various antitumor agents for different cancers, this highlights the need to employ effective MCL1 inhibitors that can be used either as a single agent or in combination regimens [21]. The gene discussed is MCL1; the disease is cancer.